Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Jazz Pharmaceuticals excels in Q3 with record sales and growth

Jazz Pharmaceuticals' Q3 2024 performance reflects strong revenue growth and operational resilience, driven by key products and ongoing innovation efforts.
While facing challenges like revenue impact for Rylaze, the company remains focused on normalizing demand and advancing its pipeline programs.
With a solid financial foundation and a strategic focus on high-potential areas, Jazz Pharmaceuticals is well-positioned to capitalize on growth opportunities.
By affirming revenue guidance, investing in innovation, and exploring business development prospects, Jazz Pharmaceuticals demonstrates a commitment to long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Redx Pharma PLC (AIM:REDX) said it is sellling its KRAS inhibitor programme to Nasdaq-listed Jazz Pharma Inc in a deal with a headlne value of $880 million. Under the terms of the transaction, Redx will receive an upfornt $10 million followed by $870 million in development, regulatory, and sales milestone payments.

Redx Pharma inks $880m deal with Jazz Pharma; will bank $10m immediately

Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales Preclinical program expands Jazz's pipeline of targeted oncology therapies DUBLIN and ALDERLEY PARK, United Kingdom , Feb. 7, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies have signed a definitive agreement under which Jazz will acquire Redx's KRAS (Kirsten rat sarcoma virus) inhibitor program. Jazz and Redx will collaborate to advance candidates through IND-enabling studies; Jazz will be responsible for all clinical development, regulatory, manufacturing and commercialization activities.

Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

AbbVie

Eli Lilly

There is a lot of good news to digest from the biotech sector. Not only does it offer lots of strong stocks in January, but it is also expected to grow rapidly.

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024

Jazz Pharmaceuticals is likely to fall short of its 2025 revenue goal of $5 billion unless it makes a bold M&A move. Despite this, the stock looks undervalued and has the potential to re-rate higher, driven by the growth of Xywav, Rylaze, and Epidiolex, as well as upcoming pipeline readouts and business development. The fears over the oxybate franchise's demise are overblown and Xywav is likely to retain a good portion of its sales despite increasing competition and availability of generic Xyrem.

Updated View On Jazz Pharmaceuticals' 2025 Goals

Pfizer

Healthcare is a multitrillion-dollar industry, and long-term investors can capitalize on this space in a variety of ways. Pfizer may not be living up to pandemic-era expectations, but investors need to take a closer look.

2 Incredible Growth Stocks That Are Screaming Buys for 2024

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) received an Outperform rating and a target price of $160 from Baird, citing optimistic expectations for the company's performance in the coming year. Initiating coverage of the stock, Baird analysts are anticipating a positive trend for Jazz over the next year, driven primarily by the growth of key business products, particularly Xywav – a narcolepsy treatment – and Epidiolex, an oral cannabinoid solution for severe epilepsy.

Jazz Pharmaceuticals targets positive momentum in 2024, receives Outperform rating

Contango ORE

Devon Energy

Franco-Nevada C

IMAX

Sturm, Ruger & Company

Target Hospitality Corp

With the Federal Reserve previously engaged in a bitter – and seemingly, at times desperate – struggle against blisteringly hot inflation, the narrative for growth stocks to buy now frankly didn't resonate very well with many investors. However, a possible policy pivot could change everything.

7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World

Allegro MicroSystems

Calix

Celsius Holdings

Civitas Resources

Darling Ingredients

Frontier Communications Corporation

HealthEquity

Interactive Brokers

Iridium Communications

Lantheus Holdings

MP Materials

Matador Resources

Perrigo

R1 RCM Inc

Teradata

TKO Group Holdings Inc

United Therapeutics

Valaris Ltd

Essential Utilities

When investors think about whether to increase their exposure beyond the big companies that grab most of the headlines in the financial media, they are likely to look at small-cap stocks first. After all, the sky's the limit.

20 midcap stocks with 2024 upside ranging up to 62%, according to analysts

After a mid-stage study fails to show any improvement in its primary or secondary endpoints, Jazz (JAZZ) plans to scrap the development of its PTSD drug.

Jazz Pharmaceuticals' (JAZZ) PTSD Drug Misses Study Goals

Jazz Pharmaceuticals said on Thursday its post-traumatic stress disorder (PTSD) drug failed to meet the main goal in a mid-stage study.

Jazz Pharmaceuticals' PTSD drug fails in mid-stage trial

DUBLIN , Dec. 21, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced top-line results from the Phase 2 trial (NCT05178316) evaluating JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy and safety in adults with post-traumatic stress disorder (PTSD). The trial did not meet the primary endpoint.

Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder

Jazz Pharmaceuticals' market valuation is fairly conservative overlooking its promising potential. Zanidatamab's Phase 2a success boosts Jazz's oncology market potential. Despite challenges, Jazz's strategic positioning and conservative market valuation provide deep value for interested investors.

Jazz Pharmaceuticals' Zanidatamab Promises Growth Amidst Market Undervaluation

DUBLIN , Dec. 20, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 42nd Annual J.P. Morgan Healthcare Conference.

Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

First presentation of progression-free survival (PFS) primary endpoint data show zanidatamab plus palbociclib and fulvestrant demonstrated a PFS of 67% at 6 months and a median PFS of 12 months in patients with heavily pre-treated HER2+/HR+ metastatic breast cancer (mBC) Efficacy and safety results support further investigation of this targeted combination therapy as a potential chemotherapy-free option for patients with HER2+/HR+ mBC DUBLIN , Dec. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today presented updated data from the Phase 2a trial of investigational zanidatamab, a HER2-targeted bispecific antibody, in combination with palbociclib, a CDK4/6 inhibitor, and fulvestrant, a selective estrogen receptor antagonist, in patients with HER2-positive (HER2+)/HR-positive (HR+) metastatic breast cancer (mBC) as part of a late-breaking oral presentation at the 2023 San Antonio Breast Cancer Symposium (SABCS). Data from 51 patients with heavily pretreated HER2+/HR+ mBC (median of 4 prior regimens in the metastatic setting) who were treated with zanidatamab plus palbociclib and fulvestrant demonstrated a progression-free survival at six months (PFS6) of 67% (n=34) [95% confidence interval: 52, 79].

Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Why Is Jazz (JAZZ) Up 2.6% Since Last Earnings Report?

Data from nine abstracts to be presented, including real-world outcomes of Epidiolex® (cannabidiol) in treatment-resistant focal epilepsies Presentations include data on U.S. caregiver-reported seizure and non-seizure outcomes in patients with tuberous sclerosis complex prescribed Epidiolex  DUBLIN , Dec. 1, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that nine company-sponsored presentations, including five late-breaking abstracts, will be shared at the 2023 American Epilepsy Society (AES) annual meeting, being held December 1-5 in Orlando, Florida. Late-breaking presentations include a post-hoc analysis examining real-world outcomes of Epidiolex® (cannabidiol) in treatment-resistant focal epilepsies within the Expanded Access Program (EAP), as well as a post-hoc analysis of the GWPCARE6 Open-Label Extension (OLE) trial evaluating the effectiveness of Epidiolex as add-on therapy against focal seizures in tuberous sclerosis complex (TSC).

Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting

New trial results of  investigational bispecific antibody zanidatamab presented at SABCS in HER2+/HR+ metastatic breast cancer Strong presence at ASH includes 11 presentations spanning Jazz's portfolio, advancing research into difficult-to-treat blood cancers and diseases Real-world data at NACLC reinforce clinical impact of Zepzelca® (lurbinectedin) in small cell lung cancer DUBLIN , Nov. 30, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company and its partners will present two abstracts at the 2023 San Antonio Breast Cancer Symposium (SABCS) from December 5-9; 11 abstracts at the 65th Annual American Society of Hematology (ASH) Annual Meeting from December 9-12; and two abstracts at the International Association for the Study of Lung Cancer (IASLC) 2023 North America Conference on Lung Cancer (NACLC) from December 1-3. New data include updated findings from a Phase 2a trial of the investigational HER2-targeted bispecific antibody zanidatamab in combination with palbociclib and fulvestrant as a chemotherapy-free option for HER2+/ HR+ metastatic breast cancer (mBC).

Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings

Amylyx Pharmaceuticals

Vertex Pharmaceuticals

Investing in biotech stocks is not for risk-averse investors. However, if you're an investor who is serious about generating outsized gains, it's a sector that you can't overlook.

3 Top-Rated Biotech Stocks That Analysts Are Loving Now

STEVENAGE, England--(BUSINESS WIRE)--Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony.

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

Jazz (JAZZ) reports mixed results in third-quarter 2023. However, shares rose 2.5% post the announcement, likely on the back of raised guidance for 2023.

Jazz (JAZZ) Lags Q3 Earnings, Beats Sales, Raises '23 View

Alkermes

Amphastar Pharma

Ginkgo Bioworks Holdings

DaVita

OraSure Technologies

If you're a fan of the hit TV show Shark Tank, you've probably come across the intriguing term “unicorn” companies. Indeed, these fantastical entities are not only confined to the realm of imagination.

7 Healthcare Stocks That Are Poised to Become the Next Unicorns

– 3Q23 total revenues of $972 million –– Combined revenues from key growth drivers, Xywav®, Epidiolex® and Rylaze®, increased 24% year-over-year –– Raising total and Oncology revenue guidance at the mid-points –– Plan to initiate zanidatamab rolling biologics license application (BLA) submission this year for accelerated approval in second-line (2L) biliary tract cancers (BTC) – DUBLIN , Nov. 8, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the third quarter of 2023 and provided business updates. "We have once again delivered strong financial results from increasingly diversified revenue streams and remain well-positioned for long-term growth.

Jazz Pharmaceuticals Announces Third Quarter 2023 Financial Results and Updates Financial Guidance

Besides Wall Street's top -and-bottom-line estimates for Jazz (JAZZ), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.

Unlocking Q3 Potential of Jazz (JAZZ): Exploring Wall Street Estimates for Key Metrics

Aurora Cannabis

Canopy Growth

Cronos Group

MedMen Enterprises Inc.

SNDL Inc.

AdvisorShares Pure Cannabis ETF 

The rollercoaster ride of the cannabis market has left many in the investing world dazed and confused. The sector's volatility is marked by winds of optimism followed by spells of disappointment.

Cannabis Cash Burn Concerns? Sell These 7 Overbought Stocks Now.

DUBLIN and HOUSTON, Nov. 7, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and The University of Texas MD Anderson Cancer Center today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers. The collaboration will combine MD Anderson's translational medicine and clinical research expertise with Jazz's expanding oncology drug development capabilities to investigate the potential of zanidatamab as monotherapy and in combination with other treatments for patients with different tumor types and stages.

News for Jazz Pharmaceuticals Stock (JAZZ)